目的 觀察及探討急性腦梗死應(yīng)用阿替普酶溶栓后聯(lián)合注射用丹參多酚酸治療的臨床效果。方法 選取新鄉(xiāng)市中心醫(yī)院2018年1月-2018年6月首發(fā)急性腦梗死患者71例，其中對照組患者35例，進(jìn)行阿替普酶靜脈溶栓治療，治療組患者36例，在對照組基礎(chǔ)上應(yīng)用注射用丹參多酚酸0.13 g/d，共治療14 d。對比兩組治療效果及兩組分別治療第7天及第14天的美國國立衛(wèi)生研究院卒中量表（NIHSS）評分和改良RANKIN量表（MRS）評分進(jìn)行觀察比較。結(jié)果 治療組治療總有效率高于對照組，差異具有統(tǒng)計學(xué)意義（P<0.05）。治療第1天時，NIHSS評分及MRS評分無統(tǒng)計學(xué)差異；治療第7、14天時，兩組NIHSS評分均降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；治療第14天時，觀察組NIHSS評分明顯低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。在日常生活能力方面，治療組與對照組在第7天時，MRS評分無論是組間比較還是組內(nèi)比較，均無明顯差異性；但在第14天時，無論組間比較還是組內(nèi)比較，MRS評分均有明顯的差異性且有顯著的統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 急性腦梗死進(jìn)行阿替普酶溶栓后聯(lián)合注射用丹參多酚酸治療能夠有效的改善神經(jīng)功能缺損癥狀及顯著提高日常生活自理能力，尤其在腦梗死1周之后臨床效果更加顯著，值得臨床推廣和應(yīng)用。

Objective To observe and investigate the clinical efficacy of alteplase combined with Salvianolic Acids for Injection for patients with acute cerebral infarction. Methods From January 2018 to June 2018, 71 patients with acute cerebral infarction who underwent intravenous thrombolysis with alteplase were were randomly assigned to treatment group (36 cases) and control group (35 cases). Patients in treatment group received Salvianolic Acids for Injection at 0.13 g/day dosage for 14 days. Patients in the control group were given routine treatment. The scores of the United States national institutes of health stroke scale (NIHSS) and modified RANKIN scale (MRS) after treatment at 7, 14 days were compared between two groups. Results The total effective rate of the treatment group was higher than that of the control group, and the difference was significant (P<0.05). On the first day of treatment, there was no statistical difference in NIHSS score and MRS score; on the seventh and fourteenth days of treatment, the NIHSS score of both groups decreased, and there was significant difference before and after treatment in the same group (P<0.05); on the fourteenth day of treatment, the NIHSS score of the observation group was significantly lower than that of the control group (P<0.05). In terms of daily living ability, there was no significant difference in MRS score between the treatment group and the control group on the 7th day, but on the 14th day, there was significant difference in MRS score between the two groups (P<0.05). Conclusion The treatment of alteplase thrombolysis combined with Salvianolic Acids for Injection for acute cerebral infarction can effectively improve the symptoms of neurological functional defects and significantly improve the ability of self-care in daily life, especially one week later, which is deserved the clinical expansion.